Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1948 1
1960 1
1962 1
1963 1
1964 3
1965 1
1973 1
1974 1
1975 2
1976 3
1977 4
1978 1
1980 10
1981 4
1982 2
1983 3
1984 6
1985 6
1986 14
1987 9
1988 14
1989 11
1990 20
1991 17
1992 22
1993 22
1994 37
1995 36
1996 35
1997 41
1998 47
1999 48
2000 73
2001 99
2002 80
2003 121
2004 116
2005 184
2006 223
2007 262
2008 369
2009 387
2010 467
2011 593
2012 660
2013 799
2014 951
2015 1049
2016 1100
2017 1312
2018 1599
2019 1756
2020 2109
2021 2538
2022 2988
2023 2861
2024 3214
2025 3508
2026 61

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

26,826 results

Results by year

Filters applied: . Clear all
Page 1
Trichothiodystrophy.
Li Q, Bi L, Ji H, Yang F, Chen J. Li Q, et al. Among authors: yang f. Br J Dermatol. 2025 Dec 9:ljaf505. doi: 10.1093/bjd/ljaf505. Online ahead of print. Br J Dermatol. 2025. PMID: 41365819 No abstract available.
Bradykinin-bradykinin 2 receptor and oxidative stress.
Zhao J, Wang Z, Wang X, Yang F, Xi H, Wen J, Zhang W, Qiu X. Zhao J, et al. Among authors: yang f. Ann Med. 2025 Dec;57(1):2581151. doi: 10.1080/07853890.2025.2581151. Epub 2025 Nov 3. Ann Med. 2025. PMID: 41178473 Free PMC article. Review.
Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): final analysis of a randomised, open-label, international, phase 3 study.
Qin S, Gu S, Chan SL, Bai Y, Ren Z, Lin X, Chen Z, Jia W, Jin Y, Guo Y, Hu X, Meng Z, Liang J, Xiong J, Ren H, Yang F, Li W, Chen Y, Zeng Y, Xu L, Yuan X, Li D, Sultanbaev A, Pazgan-Simon M, Pisetska M, Melisi D, Ponomarenko D, Du J, Shi W, Cheng AL, Kaseb A, Vogel A; CARES-310 Study Group. Qin S, et al. Among authors: yang f. Lancet Oncol. 2025 Dec;26(12):1598-1611. doi: 10.1016/S1470-2045(25)00543-1. Lancet Oncol. 2025. PMID: 41308676 Clinical Trial.
Elucidating pathway-selective biased CCKBR agonism for Alzheimer's disease treatment.
Wang JL, Sha XY, Shao Y, Zhang ZH, Huang SM, Lin H, Gan SY, Zhang N, Xia XY, Sun YN, Ding JH, Zhao RQ, Cheng J, Shang P, Wang JP, Liu YJ, Yang F, Xiao P, Wang LW, Zhao DY, Tang Y, Tie L, Du Y, Zhang Y, He JF, Sun JP. Wang JL, et al. Among authors: yang f. Cell. 2025 Nov 20:S0092-8674(25)01238-3. doi: 10.1016/j.cell.2025.10.034. Online ahead of print. Cell. 2025. PMID: 41270732
[Textual research on Zhenjiu Neipian].
Wang R, Bao B, Song B, Yang F. Wang R, et al. Among authors: yang f. Zhongguo Zhen Jiu. 2025 Nov 12;45(11):1689-1694. doi: 10.13703/j.0255-2930.20250210-k0002. Epub 2025 Aug 25. Zhongguo Zhen Jiu. 2025. PMID: 41261558 Chinese.
Advancements in Photodynamic Therapy for Tuberculosis Treatment.
Lin S, Zhang Q, Liu J, Lin B, Zhao D, Yang J, Fang J, Xu JF, Pi J, Yang F. Lin S, et al. Among authors: yang f. Microb Pathog. 2025 Nov 30:108207. doi: 10.1016/j.micpath.2025.108207. Online ahead of print. Microb Pathog. 2025. PMID: 41330473 Review.
26,826 results
You have reached the last available page of results. Please see the User Guide for more information.